ASKG 915
Alternative Names: ASKG-915Latest Information Update: 24 Jul 2026
At a glance
- Originator AskGene Pharma
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 receptor agonists; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jun 2026 Efficacy and adverse events data from a phase-I clinical trials in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 03 Aug 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT05867420)
- 22 May 2023 AskGene Pharma plans a phase I trial for Solid tumours (Second-line therapy or greater, Late-stage disease) in Unknown location (IV) in June 2023 (NCT05867420)